Probiotic chief: “[Collaboration] could be part of the puzzle for health claim applications”

Swedish firm engages Wageningen to reveal probiotic mechanism of action

By Shane STARLING contact

- Last updated on GMT

Probi: “We see this collaboration as an important step in our future product development.”
Probi: “We see this collaboration as an important step in our future product development.”
A Swedish probiotic player has enlisted Wageningen University to research probiotic mechanisms of action in the area of inflammation – work Probi’s CEO told us could yield a sector-defining health claim.

“Discovering probiotic mechanisms of action is the right way to go,” ​said Peter Nählstedt. “This research can help with health claims because many EFSA opinions have demanded mechanism of action data so it could be part of the puzzle for health claim applications.”

The work will interest EU health claim observers and probiotics players as mechanisms of action are an area the European Food Safety Authority (EFSA) has noted is weak in the sector.

Probi will link with professor Michiel Kleerebezem at Wageningen’s Host Microbe Interactomics Group​ on the 4-year PhD project.

Probiotics are best known for their gut and immune benefits but mechanisms of action have proved difficult to define. Here the aim will be anti-inflammation mechanisms of action and identifying the most viable strains both “known and unknown” in vitro​ and in vivo​.

Wageningen University is one of Europe’s leading food research institutions. Kleerebezem’s unit has worked in areas such as cell biology, immunology, microbiology and functional genomics “to increase the understanding of molecular interactions occurring in the cross-talk between microbes and their hosts.”

Bacteria_petridish_food_Safety_iStock

Nählstedt added in a statement: “We see this collaboration as an important step in our future product development.”

“I personally believe that this project will lead to a much better understanding of anti-inflammatory probiotics and provide an opportunity for Probi to develop novel products in new and interesting fields.”

Probi has strain supply deals with Danone and its US subsidiary Dannon and recently signed an €18m deal​ with US supplements firm NBTY, which owns UK-based health food retail chain Holland & Barrett.

Related news

Show more

Related products

show more

Highly bioavailable and stable source of iron

Highly bioavailable and stable source of iron

Lipofoods, a Lubrizol Company | 22-Nov-2017 | Infographic

LIPOFER™ is a water-dispersible micronized source of iron that has been microencapsulated to boost iron absorption and reduce unwanted organoleptic characteristics....

Mother’s milk selects Bifidobacteria in the infant gut

Mother’s milk selects Bifidobacteria in the infant gut

Morinaga Milk Industry Co., Ltd. | 21-Nov-2017 | Technical / White Paper

Health promoting traits of Bifidobacteria are strain-specific, however, whether the residential origin of each species would also contribute to the differences...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars